EA039037B1 - Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение - Google Patents

Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение Download PDF

Info

Publication number
EA039037B1
EA039037B1 EA201691120A EA201691120A EA039037B1 EA 039037 B1 EA039037 B1 EA 039037B1 EA 201691120 A EA201691120 A EA 201691120A EA 201691120 A EA201691120 A EA 201691120A EA 039037 B1 EA039037 B1 EA 039037B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ifn
mva
virus
cells
protein
Prior art date
Application number
EA201691120A
Other languages
English (en)
Russian (ru)
Other versions
EA201691120A1 (ru
Inventor
Юрген Хаусманн
Михаэль Вольферштеттер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA201691120A1 publication Critical patent/EA201691120A1/ru
Publication of EA039037B1 publication Critical patent/EA039037B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201691120A 2013-11-28 2014-11-25 Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение EA039037B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13005541 2013-11-28
PCT/EP2014/075522 WO2015078856A1 (en) 2013-11-28 2014-11-25 Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors

Publications (2)

Publication Number Publication Date
EA201691120A1 EA201691120A1 (ru) 2016-09-30
EA039037B1 true EA039037B1 (ru) 2021-11-24

Family

ID=49680779

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691120A EA039037B1 (ru) 2013-11-28 2014-11-25 Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение

Country Status (22)

Country Link
US (2) US20160376596A1 (enExample)
EP (2) EP3074517B1 (enExample)
JP (2) JP6641276B2 (enExample)
KR (1) KR102504316B1 (enExample)
CN (1) CN105829537B (enExample)
AU (3) AU2014356546A1 (enExample)
BR (1) BR112016011866A2 (enExample)
CY (1) CY1124707T1 (enExample)
DK (1) DK3074517T3 (enExample)
EA (1) EA039037B1 (enExample)
ES (1) ES2895977T3 (enExample)
HU (1) HUE056105T2 (enExample)
IL (1) IL245509B (enExample)
LT (1) LT3074517T (enExample)
MX (1) MX377258B (enExample)
MY (1) MY188100A (enExample)
NZ (2) NZ719934A (enExample)
PT (1) PT3074517T (enExample)
SI (1) SI3074517T1 (enExample)
UA (1) UA127337C2 (enExample)
WO (1) WO2015078856A1 (enExample)
ZA (1) ZA201603187B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272546B2 (en) * 2017-08-24 2024-01-01 Bavarian Nordic As Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP3957322A1 (en) * 2020-08-19 2022-02-23 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant poxviridae vector expressing co-stimulatory molecules
US20240245765A1 (en) * 2021-05-13 2024-07-25 Thomas Jefferson University Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
CN115043948B (zh) * 2022-06-24 2024-05-28 青岛硕景生物科技有限公司 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用
GB202407035D0 (en) * 2024-05-17 2024-07-03 Uncommon Bio Ltd RNA constructs with immune blocking agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2027033A (en) * 1978-07-28 1980-02-13 Green Cross Corp Double-stranded rna
US20050281782A1 (en) * 2004-06-21 2005-12-22 Howard Kaufman Novel recombinant poxvirus composition and uses thereof
US20060073594A1 (en) * 2004-10-05 2006-04-06 Jiansheng Yao Chimeric vectors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU774076C (en) * 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
ATE386127T1 (de) * 1999-04-08 2008-03-15 Novartis Vaccines & Diagnostic Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
AU2003249059A1 (en) * 2002-07-24 2004-02-09 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
WO2006069064A2 (en) * 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2027033A (en) * 1978-07-28 1980-02-13 Green Cross Corp Double-stranded rna
US20050281782A1 (en) * 2004-06-21 2005-12-22 Howard Kaufman Novel recombinant poxvirus composition and uses thereof
US20060073594A1 (en) * 2004-10-05 2006-04-06 Jiansheng Yao Chimeric vectors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHARLIE GARNETT, JOHN GREINER, KWONG-YOK TSANG, CHIE KUDO-SAITO, DOUGLAS GROSENBACH, MALA CHAKRABORTY, JAMES GULLEY, PHILIP ARLEN,: "TRICOM Vector Based Cancer Vaccines", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, vol. 12, no. 3, 1 January 2006 (2006-01-01), pages 351 - 361, XP055110442, ISSN: 13816128, DOI: 10.2174/138161206775201929 *
DMITRIEV, I.P. KHROMYKH, A.A. IGNATYEV, G.M. GAINULLINA, M.N. AGEENKO, V.A. DRYGA, S.A. VOROBYEVA, M.S. SANDAKHCHIEV, L.S.: "Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 44, no. 1, 26 January 1996 (1996-01-26), Amsterdam NL , pages 97 - 103, XP004036854, ISSN: 0168-1656, DOI: 10.1016/0168-1656(95)00141-7 *
VIJAYSRI, S. JENTARRA, G. HECK, M.C. MERCER, A.A. MCINNES, C.J. JACOBS, B.L.: "Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Intra-nasal vaccination", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 5, 4 December 2007 (2007-12-04), AMSTERDAM, NL , pages 664 - 676, XP022419778, ISSN: 0264-410X *
WOLFERSTAETTER MICHAEL; SCHWENEKER MARC; SPAETH MICHAELA; LUKASSEN SUSANNE; KLINGENBERG MARIEKEN; BRINKMANN KAY; WIELERT URSULA; L: "Recombinant Modified Vaccinia Virus Ankara Generating Excess Early Double-Stranded RNA Transiently Activates Protein Kinase R and Triggers Enhanced Innate Immune Responses", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 88, no. 24, 1 December 2014 (2014-12-01), US , pages 14396 - 14411, XP009182480, ISSN: 0022-538X, DOI: 10.1128/JVI.02082-14 *

Also Published As

Publication number Publication date
CY1124707T1 (el) 2022-07-22
US12644125B2 (en) 2026-06-02
KR20160087814A (ko) 2016-07-22
PT3074517T (pt) 2021-11-03
HUE056105T2 (hu) 2022-01-28
IL245509A0 (en) 2016-06-30
EP3971298A2 (en) 2022-03-23
EP3074517B1 (en) 2021-08-11
JP7050044B2 (ja) 2022-04-07
UA127337C2 (uk) 2023-07-26
AU2021200985A1 (en) 2021-03-11
DK3074517T3 (da) 2021-11-08
IL245509B (en) 2020-09-30
EP3971298A3 (en) 2022-04-27
ES2895977T3 (es) 2022-02-23
US20160376596A1 (en) 2016-12-29
AU2014356546A1 (en) 2016-06-02
JP2017503479A (ja) 2017-02-02
LT3074517T (lt) 2021-11-25
NZ719934A (en) 2022-10-28
WO2015078856A1 (en) 2015-06-04
NZ759538A (en) 2022-10-28
ZA201603187B (en) 2023-12-20
MX2016006758A (es) 2016-09-06
BR112016011866A2 (pt) 2017-09-26
AU2024202790A1 (en) 2024-07-04
JP6641276B2 (ja) 2020-02-05
KR102504316B1 (ko) 2023-02-24
EP3074517A1 (en) 2016-10-05
CA2929600A1 (en) 2015-06-04
CN105829537B (zh) 2020-09-22
MY188100A (en) 2021-11-18
AU2021200985B2 (en) 2024-02-01
SI3074517T1 (sl) 2021-12-31
CN105829537A (zh) 2016-08-03
US20200325477A1 (en) 2020-10-15
EA201691120A1 (ru) 2016-09-30
MX377258B (es) 2025-03-07
AU2024202790B2 (en) 2026-06-04
JP2020072693A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2021200985B2 (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
JP6818797B2 (ja) 強靭なt細胞用のpr13.5プロモータ及び抗体応答
US20210299236A1 (en) Methods and Compositions for Enhancing Vaccine Immune Responses
CA2741724C (en) Promoters for recombinant viral expression
EP3197490B1 (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
EP2864487B1 (en) Poxviral vectors for low antibody response after a first priming immunization
JP2012520061A (ja) 複製欠損性組換えウイルスワクチン中の抗原に対する細胞傷害性t細胞応答に有利である反復ワクチン接種と組み合わされた最適化初期−後期プロモーター
CA2725383A1 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
WO2004087047A2 (en) Mutants of replication competent vaccinia virus
HK40072005A (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
CA2929600C (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
HK1226774B (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
HK1226774A1 (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
Cottingham et al. Recombination-Mediated Genetic Engineering of a Bacterial Artificial
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses